Efficacy of N,N‘bis-(2-mercaptoethyl) isophthalamide on mercury intoxication: a randomized controlled trial

Table 5 Summary of changes from baseline in urine values

Treatment	Visit	Median	p-value*
Mercury in urine [μg/l]
NBMI 100 mg	Day 15	−6.4 (− 128.6–76.1)	.892
NBMI 100 mg	Day 45	−1.5 (− 126.5–22.2)	.812
NBMI 300 mg	Day 15	−8.2 (− 240.9–0.8)	.011
NBMI 300 mg	Day 45	−6.0 (− 246.9–6.8)	.069
Placebo	Day 15	2.7 (−71.9–45.9)
Placebo	Day 45	0.1 (−74.7–49.3)
Mercury in urine [μg/g creatinine]
NBMI 100 mg	Day 15	8.2 (− 135.9–122.8)	.849
NBMI 100 mg	Day 45	−13.8 (− 140.2–232.5)	.894
NBMI 300 mg	Day 15	−24.6 (− 475.5–79.0)	.091
NBMI 300 mg	Day 45	−4.0 (− 463.3–1110.1)	.722
Placebo	Day 15	1.8 (−407.9–297.1)
Placebo	Day 45	−5.9 (− 453.7–1557.8)

Results give the median values measured at each time point. Change of baseline is the difference of the day 15/day 45 value and baseline value in each individual. The median of calculated differences is shown
*Wilcoxon-Mann-Whitney test for differences in change from baseline between treatment groups and placebo

ISSN: 1476-069X